30价M蛋白mRNA A组链球菌疫苗的免疫原性
本研究在雌性新西兰白兔中比较了30价M蛋白mRNA疫苗(可溶性mRNA与C端跨膜mRNA两种配方)与30价蛋白疫苗的免疫原性,并以不可翻译RNA为对照,各配方于第1、28、56天接种3剂。结果显示mRNA疫苗与蛋白疫苗诱导的血清IgG水平及调理吞噬杀伤活性相似,C端跨膜mRNA疫苗抗体水平略高于可溶性mRNA疫苗。
要点
- mRNA疫苗与蛋白疫苗诱导的血清IgG水平相似。
- C端跨膜mRNA疫苗抗体水平略高于可溶性mRNA疫苗。
- mRNA与蛋白疫苗的调理吞噬杀伤活性相似,与M型别无关。
核心结论
- 30价mRNA A组链球菌疫苗诱导的总抗体应答和功能性抗体水平与同类蛋白疫苗相似。
- mRNA疫苗平台相比蛋白疫苗具有潜在优势,包括固有佐剂活性、更高的生产效率、更低的成本以及快速更换表位/肽段的潜力。
研究设计与样本
- 雌性新西兰白兔随机接种四种疫苗配方之一,每种配方于第1、28、56天接种3剂。
- 四种配方分别为:可溶性mRNA(100 μg/只)、C端跨膜mRNA(100 μg/只)、蛋白疫苗(400 μg/只)、不可翻译RNA对照(100 μg/只)。
- 于首剂前1天及第42天和第70天采集血清,用ELISA检测针对合成M肽的抗体水平,并用HL-60调理吞噬杀伤(OPK)试验评估功能性抗体水平。
主要发现
- mRNA疫苗与蛋白疫苗诱导的血清IgG水平相似。
- C端跨膜mRNA疫苗诱导的抗体水平略高于设计表达可溶性蛋白的mRNA疫苗。
- 无论M型别如何,mRNA疫苗与蛋白疫苗的OPK活性相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Group A Streptococcus (Strep A) causes both uncomplicated and severe invasive infections, as well as the post-infection complications acute rheumatic fever and rheumatic heart disease. Despite the high global burden of disease resulting from Strep A infections, there is not a licensed vaccine. A 30-valent M protein-based vaccine has previously been shown to be immunogenic in animal models and in a Phase I clinical trial (NCT02564237). Here, we assessed the immunogenicity of a 30-valent messenger (m)RNA vaccine designed to express the same M peptide targets as the 30-valent protein vaccine and compared it with the protein vaccine. METHODS: Female New Zealand white rabbits were immunized with one of four vaccine formulations (3 doses of each formulation at days 1, 28, and 56): soluble mRNA (100 μg/animal), C-terminal transmembrane mRNA (100 μg/animal), protein vaccine (400 μg/animal), or a non-translatable RNA control (100 μg/animal). Serum was collected one day prior to the first dose and on days 42 and 70. Rabbit serum samples were assayed for antibody levels against synthetic M peptides by ELISA. HL-60 opsonophagocytic killing (OPK) assays were performed to assess functional antibody levels. RESULTS: Serum IgG levels were similar for the mRNA and protein vaccines. The CtTM version of the mRNA vaccine elicited slightly higher antibody levels than the mRNA designed to express soluble proteins. OPK activity was similar for the mRNA and protein vaccines, regardless of M type. CONCLUSIONS: The total antibody responses and functional antibody levels elicited by the 30-valent mRNA Strep A vaccines were similar to those observed following immunization with the analogous protein vaccine. The mRNA vaccine platform provides potential advantages to protein-based vaccines including inherent adjuvant activity, increased production efficiency, lower cost, and the potential to rapidly change epitopes/peptides, all of which are important considerations related to multivalent Strep A vaccine development.
引用
- Finn MB, Penfound TA, Salehi S, et al. Immunogenicity of a 30-valent M protein mRNA group A Streptococcus vaccine. Vaccine. 2024. PMID: 39141987. doi:10.1016/j.vaccine.2024.126205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。